The Role of Verbal Memory in Masking Alzheimer's Disease Symptoms in Women

Sasha Novozhilova[1] (MSc), Vladimir Fonov[1] (PhD), Neda Shafie[1] (MSc), Denise Klein[1,2] (PhD), Sylvia Villeneuve[1,3,4] (PhD), D. Louis Collins[1,2] (PhD), for the ADNI and PREVENT-AD research groups

Affiliations:

1: McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University

2: Department of Neurology and Neurosurgery, McGill University

3: Department of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada

4: Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University

Corresponding author: D. Louis Collins (louis.collins@mcgill.ca)

Manuscript word count: 2,995

Key points

Question: Do men and women show different trajectories of verbal memory decline in relation to Alzheimer's disease onset?

Findings: This longitudinal study of 987ADNI and PREVENT-AD participants found that women maintained normal verbal learning performance 2.4 years longer before AD diagnosis than men but declined 0.53 points per year faster once deterioration began, with differences driven primarily by early trials.

Meaning: Women's inherent superior verbal memory ability masks the early signs of AD and leads to accelerated cognitive decline.

Structured abstract (word count: 343)

Importance: Women are consistently reported to experience steeper rates after an Alzheimer's disease (AD) diagnosis. We tested if this could be due to a sex-specific cognitive reserve based in verbal memory.

Objective: To determine whether the divergence in verbal memory trajectories from cognitively normal (CN) to AD varies by sex.

Design: We employed a longitudinal cohort design (ADNI, PREVENT-AD) to model cognitive change over time in Aβ- CN participants versus Aβ+ participants that progressed to AD.

Setting: The study was conducted in two longitudinal research cohorts. ADNI is multi-site initiative recruiting through clinical referrals and digital outreach, while PREVENT-AD, based at the Douglas Hospital, recruits individuals with a familial history of AD.

Participants: Both ADNI and PREVENT-AD aim to characterize AD. At baseline, ADNI participants may have normal cognition (CN), mild cognitive impairment or dementia, while PREVENT-AD participants were all CN. For this study, we harmonized CN participants from both cohorts as controls and defined the AD trajectory group as Aβ+ ADNI participants diagnosed with AD at baseline or during follow-up.

Main Outcome(s) and Measure(s): The main measure used in this study was the RAVLT Immediate Recall sub-scores: Total Learning (trials 1–5), Early Learning (average of trials 1–2), and Late Learning (average of trials 4–5). All results are summarized using Bayesian Highest Density Intervals (HDI) to provide estimates of parameter uncertainty.

Results: The final sample 987 participants (440 AD) with an average of 3.9 ± 2.0 follow-up visits. Females maintained normal verbal memory longer than males, with delayed decline onset of 2.7 years (Total Learning), 3.8 years (Early Learning), and 1.4 years (Late Learning). Rates of decline differed significantly by sex: females decline by 0.5/75 points per year (Total Learning), 0.1/15 points per year (Early Learning) and 0.09/15 points per year (Late Learning).

Conclusions and Relevance: Female may mask early signs of AD through compensatory verbal mechanisms, delaying detection but contributing to sharper decline once symptoms emerge. Current testing paradigms need to explore assessments that are more sensitive to early cognitive change in females that move beyond reliance on verbal memory.

Introduction

Women account for approximately two-thirds of all Alzheimer's disease (AD) cases globally, making female sex the second most important risk factor after age[1]. AD is a progressive neurodegenerative disorder representing the most common cause of dementia worldwide[2,3]. Characterized by the accumulation of amyloid-β (Aβ) plaques[4,5] and tau neurofibrillary tangles[3,6,7], AD eventually leads to memory loss[7,8]. Standard screening protocols emphasize episodic memory, typically assessed through verbal memory tasks such as list learning and delayed recall[9–11] (e.g., RAVLT, CVLT). Emerging evidence suggests that impairments in attention and executive function, essential for successful encoding, often precede and exacerbate episodic memory decline in AD[12]. Intrinsically, immediate recall measured by the RAVLT and CVLT are sensitive to early pathological changes due to AD, reflecting disruptions in these distinct memory-related processes[13–15]. However, while these tests routinely adjust normative data for age and education, they fail to consider sex-specific norms[16,17].

Across the lifespan, women continuously outperform men in tasks requiring the encoding and retrieval of information presented in verbal form[18–21]. Paradoxically, this female verbal memory advantage may complicate and delay AD detection. Notably, the RAVLT[22] has been shown to misclassify 10% of amnestic mild cognitive impairment (aMCI) women as cognitively normal and 10% of cognitively normal men as having aMCI[23]. Although women preserve superior verbal memory abilities at the aMCI stage compared to men, this advantage has been shown to disappear and even reverse at the onset of AD[24–30]. Despite the clear cross-sectional evidence, longitudinal studies aiming to define sex-specific trajectories of verbal cognition remain sparse and lack sufficient depth[31].

Longitudinal reports show female AD patients suffering from a greater and faster loss of general function than men, possibly a consequence of being diagnosed at a later disease stage[32–34]. Thus, we hypothesize that the female verbal memory advantage serves as a sex-specific form of Cognitive Reserve (CR) that masks the early signs of decline. The verbal memory advantage, females may thus compensate for early symptoms, masking the first signs of AD until neuropathological burden is too high and initiates precipitous decline[24,33,35]. If true, this could have implications in clinical practice as a delay in diagnosis would lead in a delay of treatment, resulting in women missing critical treatment windows during early disease stages when interventions are most effective.

To address this growing concern, the current study models two cognitive change pathways: one representing stable cognition and one representing progressive decline in AD. Given that female's higher performance on verbal learning tasks has been linked to differences in encoding strategies[18], among other processes such as retrieval, we chose focused on immediate recall trials to isolate encoding-related processes[13,14]. To capture distinct phases of learning, we fractionated the RAVLT Immediate Recall Trials into Total Learning (trials 1-5), Early Learning (trials 1-2) and Late Learning (trials 4-5). Our goal is to identify the point at which the AD trajectory deviates from the stable cognition pathway and to examine how this deviation differs between sexes. Our hypotheses are that longitudinal (i) RAVLT an advantage for cognitively unimpaired Aβ- females, (ii) that the start of RAVLT decline differs between Aβ+ males and females, and finally, (iii) that the slope of RAVLT decline is sharper in Aβ+ females.

Methods

Data source

The current paper uses data obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The ADNI database includes serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessments used to measure the progression of MCI and early AD. This cohort also includes cognitively normal participants that are treated as control subjects. ADNI was launched in 2003 as a public-private partnership and performs routine follow-ups on its participants. The study received ethical approval from the review boards of all participating institutions. Written informed consent was obtained from participants or their study partners. Data used in the preparation of this study was obtained from the ADNI (adni.loni.usc.edu). Participants were selected from ADNI☐1, ADNI☐GO, ADNI☐2, and ADNI☐3. Demographic, diagnostic and APOE4 ε4 information was extracted from the ADNIMERGE table. RAVLT performance was obtained from the NEUROBAT table, and the CDR global score from CDR table. PET Aβ status was obtained from UCBERKELEY_AMY_6MM table and Aβ CSF status was obtained from UPENNBIOMK9 for those who did not have PET data available.

We also utilize data from the PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's disease (PREVENT-AD) cohort[36]. The PREVENT-AD database includes neuroimaging, biological and neuropsychiatric assessments from cognitively unimpaired individuals with a family history of sporadic AD dementia. The study received ethical approval from the McGill University review board, and all participants provided written informed consent. Data was obtained from the online sharing repository (https://registeredpreventad.loris.ca/).

Groups

All participants (Table 1) recruited in ADNI were between 55 and 90 years old at baseline. During their first visit, participants were assigned to a group based on evidence of memory decline measured by the Wechsler Memory Scale, and level of global cognition measured by the Mini Mental Status Examination (MMSE) or Clinical Dementia Rating (CDR). Cognitively Normal (CN) older adults showed no evidence of memory decline and normal global cognition. MCI participants scored between 24 and 30 on the MMSE, 0.5 on the CDR, and an abnormal score based on their ages and education on the Wechsler Memory Scale. Dementia is determined by abnormal memory function on the Wechsler Memory Scale, MMSE scores between 20 and 26, and a CDR of 0.5 or higher and a probable clinical diagnosis of AD following the criteria set by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association[37].

Participants attended an average of 3.87 ± 1.99 follow-up visits, providing sufficient longitudinal data to estimate the deviation from the normal trajectory of verbal memory cognition. To do so, we defined two groups from the ADNI data. Group A is comprised of cognitively healthy controls with Aβ- PET or CSF at all visits. Additionally, we included participants with Aβ- status from PREVENT-AD to supplement the ADNI cognitively normal cohort. For this aim, we included PREVENT-AD participants with a minimum of two visits who were Aβ-, defined by a global cortical PET SUVR ≤ 1.38. This allowed us to better characterize normal trajectories of verbal memory across a broader age range and reduce missing data at the early age range (n = 547, males = 219). Group B (n = 440, males = 249) includes all ADNI subjects that are Aβ+ *and* progressed to clinical AD (n = 280, males = 159) at some point during follow-up and AD participants who enrol with a diagnosis of clinical AD and remain stable throughout follow-up (n = 160, males = 90). For the former, the date of AD clinical onset is

estimated to be the first AD-labeled visit, while for the latter the date of onset is estimated from the year provided in the ADNI demographic table. Time to clinical disease onset (the *onset time)* for each visit is then computed by subtracting the date of each visit from the estimated date of AD diagnosis (negative onset times are measure in years prior to AD diagnosis, and zero represents the time of AD diagnosis). Aβ+ in ADNI was assessed with PET AV45 ligand (cutoff > 78 in composite regions) and FBB ligand (cutoff > 0.74 SUVr for composite regions); for participants who did not have available PET data we used a ration of CSF tTau/Aβ(1–42) (cutoff > 0.028).

Tables and figure

Table 1: Demographic Information

	Group A (Healthy Controls)		Group B (AD Trajectory)	
Variable	**Female**	**Male**	**Female**	**Male**
Participants, n	328	219	191	249
Age (mean ± SD)	69.0 ± 6.1	72.1 ± 6.4	72.4 ± 7.4	74.8 ± 7.1
Education (mean ± SD)	15.7 ± 3.0	16.8 ± 2.8	15.2 ± 2.5	16.3 ± 2.8
CDRSB	0.0 ± 0.1	0.0 ± 0.1	2.7 ± 2.0	2.7 ± 1.8
APOE ε4: 0 allele	238 (72.6%)	166 (75.8%)	56 (29.3%)	75 (30.1%)
APOE ε4: 1 allele	85 (25.9%)	51 (23.3%)	104 (54.5%)	121 (48.6%)
APOE ε4: 2 allele	5 (1.5%)	2 (0.9%)	31 (16.2%)	53 (21.3%)
PET Centiloids (CL)			89.7 ± 33.8 (n=167)	88.0 ± 36.5 (n=206)
CSF PTAU/ABETA ratio (missing CL)			0.0683 ± 0.0355 (n=24)	0.0656 ± 0.0221 (n=43)

Table 1. **Demographic and clinical characteristics of the sample,** stratified by sex, including age, education, cognitive scores, and APOE ε4 carrier status. Markers of Aβ pathology are also included for the AD trajectory group.

Statistical Analysis

Statistical modelling was performed using NumPYRO package (version 0.19.0, Python version 3.12.6). Verbal episodic memory was summarized using three outcomes reflecting different stages of cognitive processing. The immediate recall trials were fractioned into Early Learning (average of trials 1 and 2), Late Learning (average of trials 4 and 5) and Total Learning (average of trials 1-5), capturing phases of the learning curve, with early trials reflecting attentional demands and later trials indexing encoding efficiency[38]. Each outcome was modeled using a hierarchical Bayesian model that controlled for age, sex, education and APOE4 ε4 genotype, with random intercepts for repeated measurements within participants. All continuous predictors were standardized using z-scores based on the means and standard deviations of Group A subjects. The stable group's RAVLT performance was modeled with a linear regression of age, sex APOE ε4 and education. For those on the AD trajectory the deviation from this trajectory, was modeled using a smooth non-linear function of time using a SoftPlus function ($\sigma(t,d,s) = \ln(1 + e^{(t+d)}*s))/s$ where t is the onset time, d age at diagnosis and s is the SoftPlus sharpness (see supplementary materials). The SoftPlus function is a continuous, differentiable function that increases gradually from zero, allowing the model to capture the smooth onset and acceleration of decline over time without abrupt jumps, directly modeling the time shift with respect to AD onset. The sharpness parameter s was empirically set to 10 to control the width of the non-linear part of the SoftPlus function. Bayesian posterior distributions of model parameters were summarized using a 95%. Highest Density Interval (HDI), which represents the range

within which the parameters value falls with 95% probability. When looking at difference, an HDI that does not include zero indicates strong evidence for an effect. Model fit was assessed using approximate leave-one-out cross-validation (LOO), with Pareto k diagnostics used to identify highly influential observations. These checks indicated that the models provided a reasonable fit to the observed data[39].

Results

General Model Estimates

We first examined the overall model estimates, including baseline Total Learning performance and the effects of APOE genotype, education, age and sex. Figure 1 represents the full model, with the normal control trajectory depicted as a dotted line. In group A, the female-male differences in the intercept indicated that females outperformed males on all RAVLT trials (eFig. 1a). Neither age (eFig. 1b)., education (eFig. 1c)., nor APOE ε4 (eFig. 1d). status were significant predictors of the RAVLT measures. APOE ε4 genotype similarly had no effect on the estimated point at which the progressors deviated from the normal trajectory onto the AD trajectory (eFig. 2).

Figure 1

Figure 1. **Posterior Predictive Trajectories of RAVLT Immediate Recall Performance Across Age by Sex and AD Progression for a given AD diagnosis at 75y.** Panel A shows Total Learning (sum of RAVLT trials 1-5), Panel B shows Early Learning (average of trials 1 and 2), and Panel C shows Late Learning (average of trials 4 and 5). Solid lines represent predicted mean trajectories for Aβ+ participants that progress to AD, while dashed lines represent stable cognitively normal Aβ- (CN-) participants. Blue lines correspond to males, pink lines to females. Shaded regions indicate 94% highest density intervals (HDI) of the posterior predictions. Raw data points are overlaid gray X-symbols for stable CN- and semi-transparent circles for Aβ+ participants in their respective color based on sex. *Abbreviations: CN-, cognitively normal amyloid-negative; AD, Alzheimer's disease; RAVLT, Rey's Auditory Verbal Learning Test.*

Females maintain normal verbal cognition longer than males

Posterior estimates of onset time for Total Learning, Early Learning and Late Learning are presented in Figure 2. Male-female differences of onset in Total and Early Learning decline were statistically significant. Female maintained normal performance 2.7 years longer in Total Learning (95% HDI = [0.5, 4.9], Fig. 1a) and 3.8 years longer in Early Learning (95% HDI = [1.3, 6.4], Fig. 1b). The male-female difference of 1.4 years for Late Learning (95% HDI = [1.3, 6.4], Fig. 1c), was marginal with more than 5% of the posterior distribution in the negative range.

Figure 2: Posterior Mean Onset of Verbal Memory Decline with relation to AD

Figure 2. **Posterior estimates of onset of verbal memory decline relative to AD diagnosis, by sex and RAVLT sub-scores**. Forest plots show the values of the posterior mean and 95% Highest Density Interval (HDI) for males, females, and their difference (male – female). Onset is expressed in years prior to AD diagnosis. Panel A shows Total Learning (sum of RAVLT trials 1-5), Panel B shows Early Learning (average of trials 1 and 2), and Panel C shows Late Learning (average of trials 4 and 5).

Females decline faster on all aspects of verbal learning

Posterior estimates of rate of decline for Total Learning, Early Learning and Late Learning are presented in Figure 3. For Total Learning (Fig. 3a), the posterior mean male-female difference was significant at 0.54 points per year (95% HDI = [0.31, 0.77]), with a faster decline for females. A similar pattern was observed in Early Learning (Fig. 3b; 0.1 points per year, 95% HDI = [0.06, 0.15]) and Late Learning (Fig. 3c; 0.09 points per year, 95% HDI = [0.03, 0.14]), again supporting a significant female disadvantage.

Figure 3: Posterior Mean Rate of Verbal Memory Decline

Figure 3. **Posterior estimates of the rate of verbal memory decline, by sex and RAVLT subscore.** Forest plots show the values posterior mean and 94% Highest Density Interval (HDI) for males, females, and the difference (male – female). Decline is expressed in points per year. Panel A shows Total Learning (sum of RAVLT trials 1-5), Panel B shows Early Learning (average of trials 1 and 2), and Panel C shows Late Learning (average of trials 4 and 5).

Discussion

The present study provides novel longitudinal evidence for sex-specific trajectories of verbal memory decline in AD. In support of our hypothesis, we demonstrated that (i) Aβ- females show a RAVLT performance advantage (4.5/75 points for RAVLT total), (ii) the start of RAVLT decline differs by 2.7 years between males and females, and finally, (iii) that the slope of RAVLT decline is steeper in females by 0.54 points/year for RAVLT total. These results align with emerging literature proposing the that female verbal memory advantage may serve as a form of CR[31]. The delayed onset observed in women suggests that the protective effect of the verbal memory advantage is sufficient to delay detectable cognitive impairment. However, once these compensatory mechanisms are depleted, females suffer from a more precipitous rate of decline compared to males. This apparent resilience could stem from the combined effects of Early Learning advantages and underlying neuropathology[40], obscuring initial impairment and postponing clinical manifestation, ultimately delaying clinical intervention. Together, these results advance our understanding of how CR from verbal cognition operates differently across sexes and highlights the importance of sex-specific considerations in clinical assessment strategies.

Evidence for Female-Specific Tipping Point in Verbal Memory Decline

Our longitudinal analysis demonstrates the temporal dynamics of maintenance and subsequent disappearance of the verbal memory advantage, extending previous cross-sectional studies[25–27]. Our focus on immediate recall sub-scores of the RAVLT reflects the perspective that encoding processes, rather than retrieval alone, play a critical role in episodic memory[12]. Indeed, RAVLT test success depends not solely on episodic memory, but relies heavily on working memory

processes[13,14]. Neuroimaging studies identify the temporal pole as a key structure in successful performance in the early trials of the RAVLT which supports semantic organization necessary for robust encoding[13,14], whereas Late Learning relies on the Medial Temporal Lobe (MTL) to transfer information from short-term to long-term stores[41]. Thus, the greater male-female differences of 3.1 years to onset time of Early Learning compared to the marginal difference of 1.2 years to onset time of Late Learning suggests that attentional processes mediated by the temporal pole[13,14] form the foundation of the female verbal memory advantage. In other words, while early neuropathological changes primarily affect MTL[42], females may exhibit compensatory resilience in the temporal pole[25,26]. This functional and structural resilience may help maintain semantic organization; counterbalancing storage related deficits related to MTL atrophy. Future work combining neuropsychological and neuroimaging approaches are necessary to determine whether sex differences in specific brain regions contribute to these behavioral patterns.

Sex differences in tau accumulation[43], a hallmark of AD pathology closely associated with cognitive decline may help explain the differential trajectories of verbal memory decline[44,45]. Various studies have reported that females exhibit a greater level of pathological tau across all stages of the disease[28,46,47]. Studies have indeed shown that females exhibit greater tau burden in the MTL[48] but not in the temporal pole[49]. Moreover, the relationship between tau and verbal memory appears to be stronger in females compared to males in clinical groups[23,50]. In sum, although females deviate from normal cognition later than males, females are likely to harbor greater underlying pathological burden for the same level of RAVLT performance.

This greater tau burden may create a paradoxical situation: while females accumulate more pathology early in the disease process compared to males, female's verbal memory advantage

provide sufficient compensatory strength to mask this additional damage for an extended period[26]. However, once this compensatory mechanism is exhausted, the accumulated pathological burden drives a faster rate of decline. Indeed, our analysis confirmed that decline was steeper across all RAVLT sub-scores, with females loosing 0.5 more Total Learning points per year than males. Building on this mechanistic evidence, our longitudinal modeling approach is the first to precisely quantify this female-specific accelerated decline in verbal memory, providing robust temporal dynamics of the previously hypothesized female tipping point[33,51] in AD progression. This critical female point of accelerated change may reflect midlife biological transitions, such as menopause-related estrogen loss which synergize with genetic risk to accelerate neuropathological burden[52]. Future work should aim in understanding the neuropathological underpinnings of this steep decline, recognizing that neuropsychological assessments may lack sensitivity to properly detect AD symptoms in females.

Clinical Implications

Our results fundamentally challenge the adequacy of current neuropsychological assessment practices. The temporal precision of our findings is not merely a statistical concern but represents a systematic bias that could deny women access to early interventions. For instance, in the Phase 3 clinical trial of Lecanemab, inclusion criteria required a classification of MCI or mild AD dementia as defined by non-sex-normalized assessments of verbal memory[53]. As we have established, the rapid rate of cognitive decline may reflect higher underlying neuropathology, meaning that sex-blind assessments may classify women as MCI only once they are further along in the disease process[23]. This may explain why Lecanemab's benefits males but not females[53,54].

Our findings demonstrate that cognitive assessments are insufficient for detecting subtle change in early AD, particularly in females. As precision medicine advances, diagnostic tools must

account for sex-specific differences in cognitive reserve to avoid systematic underdiagnosis of women in the earliest, most treatable stages of disease. Consistent with initiatives by the National Institute in Aging[55], we advocate for the development of detection tools that target biomarkers of AD rather than relying solely on cognitive measures. Until such tools are available, it is imperative that clinicians integrate the sex-specific considerations highlighted here into their assessments to prevent delayed diagnosis and treatment in women.

Study Limitations

While this study addresses critical gaps in the literature by modelling longitudinal change in verbal memory across sexes, it does not provide evidence for the neural basis of such differences. Future studies should test the theories proposed above by investigating tau pathology in relation to cognitive decline measured with list learning assessments. The nature of combining two cohorts did not allow us to do this because there currently does not yet exist a harmonized measure for Tau accumulation[56]. Additionally, the cohorts we used were made up primarily of educated Caucasians, which may reduce generalizability. Finally, we did not include RAVLT Delayed Recall in our analyses, despite its established importance in assessing cognitive decline in AD, because the data exhibited a floor effect, with a substantial number of zeros of unknown origin. Preliminary analyses attempting to address this by removing the zeros resulted in a greatly reduced, underpowered sample, preventing reliable modeling of longitudinal change.

Conclusion

This study provides the first comprehensive longitudinal characterization of sex differences in verbal memory decline trajectories relative to AD onset. Our findings support the hypothesis that women's superior verbal memory abilities serve as a form of cognitive reserve that delays clinical detection of AD-related decline but results in steeper deterioration once compensatory

mechanisms are overwhelmed. These sex-specific patterns have significant implications for clinical practice and highlight the need for sex-aware approaches to AD assessment and intervention.

References

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health*. 2022;7(2):e105-e125.

2. Dementia. Accessed September 14, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia

3. Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. *Nat Rev Dis Primers*. 2021;7(1):33.

4. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch Neurol*. 2008;65(11):1509-1517.

5. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11(1):1-15.e1-4.

6. Wang L, Benzinger TL, Hassenstab J, et al. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. *Neurology*. 2015;84(12):1254-1260.

7. Weigand AJ, Maass A, Eglit GL, Bondi MW. What's the cut-point?: a systematic investigation of tau PET thresholding methods. *Alzheimers Res Ther*. 2022;14(1):49.

8. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. *Cold Spring Harb Perspect Med*. 2012;2(4):a006171.

9. Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. *Arch Neurol*. 1989;46(2):141-145.

10. Briceno Silva G, Arvelaez Pascucci J, Karim H, et al. Influence of the onset of menopause on the risk of developing Alzheimer's disease. *Cureus*. 2024;16(9):e69124.

11. Fernández Arias J, Therriault J, Thomas E, et al. Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer's disease. *Brain Commun*. 2023;5(3):fcad146.

12. Lattmann-Grefe R, Vockert N, Machts J, et al. Dysfunction of the episodic memory network in the Alzheimer's disease cascade. *bioRxiv*. Published online October 26, 2024:2024.10.25.620237. doi:10.1101/2024.10.25.620237

13. Putcha D, Brickhouse M, Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative. Fractionating the Rey Auditory Verbal Learning Test: Distinct roles of large-scale cortical networks in prodromal Alzheimer's disease. *Neuropsychologia*. 2019;129:83-92.

14. Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative. Fractionating verbal episodic memory in Alzheimer's disease. *Neuroimage*. 2011;54(2):1530-1539.

15. Wright LM, De Marco M, Venneri A. Current understanding of verbal fluency in Alzheimer's disease: Evidence to date. *Psychol Res Behav Manag*. 2023;16:1691-1705.

16. Gale SD, Baxter L, Connor DJ, Herring A, Comer J. Sex differences on the Rey Auditory Verbal Learning Test and the Brief Visuospatial Memory Test-Revised in the elderly: normative data in 172 participants. *J Clin Exp Neuropsychol*. 2007;29(5):561-567.

17. Mielke MM. Consideration of sex differences in the measurement and interpretation of Alzheimer disease-related biofluid-based biomarkers. *J Appl Lab Med*. 2020;5(1):158-169.

18. Kramer JH, Delis DC, Daniel M. Sex differences in verbal learning. *J Clin Psychol*. 1988;44(6):907-915.

19. Aartsen MJ, Martin M, Zimprich D, Longitudinal Aging Study Amsterdam. Gender differences in level and change in cognitive functioning. Results from the Longitudinal Aging Study Amsterdam. *Gerontology*. 2004;50(1):35-38.

20. Pauls F, Petermann F, Lepach AC. Gender differences in episodic memory and visual working memory including the effects of age. *Memory*. 2013;21(7):857-874.

21. Golchert J, Roehr S, Luck T, et al. Women outperform men in verbal episodic memory even in oldest-old age: 13-year longitudinal results of the AgeCoDe/AgeQualiDe study. *J Alzheimers Dis*. 2019;69(3):857-869.

22. Rey A. L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.) [The psychological examination in cases of traumatic encepholopathy. *Archives de Psychologie*. 1941;28:215-285.

23. Sundermann EE, Maki P, Biegon A, et al. Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI. *Neurology*. 2019;93(20):e1881-e1889.

24. Chapman RM, Mapstone M, Gardner MN, et al. Women have farther to fall: gender differences between normal elderly and Alzheimer's disease in verbal memory engender better detection of Alzheimer's disease in women. *J Int Neuropsychol Soc*. 2011;17(4):654-662.

25. Sundermann EE, Biegon A, Rubin LH, et al. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. *Neurology*. 2016;86(15):1368-1376.

26. Sundermann EE, Biegon A, Rubin LH, et al. Does the female advantage in verbal memory contribute to underestimating Alzheimer's disease pathology in women versus men? *J Alzheimers Dis*. 2017;56(3):947-957.

27. Sundermann EE, Maki PM, Rubin LH, et al. Sex differences in the relationship between temporal glucose metabolism and verbal memory performance. *Alzheimers Dement*. 2015;11(7):P51-P52.

28. Sundermann EE, Maki PM, Reddy S, Bondi MW, Biegon A, Alzheimer's Disease Neuroimaging Initiative. Women's higher brain metabolic rate compensates for early Alzheimer's pathology. *Alzheimers Dement (Amst)*. 2020;12(1):e12121.

29. Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O. Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. *Alzheimers Res Ther*. 2019;11(1):109.

30. Caldwell JZK, Berg JL, Cummings JL, Banks SJ, Alzheimer's Disease Neuroimaging Initiative. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. *Alzheimers Res Ther*. 2017;9(1):72.

31. Emrani S, Sundermann EE. Sex/gender differences in the clinical trajectory of Alzheimer's disease: Insights into diagnosis and cognitive reserve. *Front Neuroendocrinol*. 2025;77(101184):101184.

32. Lin KA, Choudhury KR, Rathakrishnan BG, et al. Marked gender differences in progression of mild cognitive impairment over 8 years. *Alzheimers Dement (N Y)*. 2015;1(2):103-110.

33. Nebel RA, Aggarwal NT, Barnes LL, et al. Understanding the impact of sex and gender in Alzheimer's disease: A call to action. *Alzheimers Dement*. 2018;14(9):1171-1183.

34. Rosende-Roca M, García-Gutiérrez F, Cantero-Fortiz Y, et al. Exploring sex differences in Alzheimer's disease: a comprehensive analysis of a large patient cohort from a memory unit. *Alzheimers Res Ther*. 2025;17(1):27.

35. Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. *Nat Rev Neurol*. 2018;14(8):457-469.

36. Villeneuve S, Poirier J, Breitner JCS, et al. The PREVENT-AD cohort: accelerating Alzheimer's disease research and treatment in Canada and beyond. *medRxiv*. Published online July 23, 2025. doi:10.1101/2025.07.22.25331791

37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939-944.

38. Almkvist O, Rennie A, Westman E, Wallert J, Ekman U. Methods for assessment of Rey Auditory Verbal Learning Test performance in memory clinic patients and healthy adults - at the cross-roads of learning theory and clinical utility. *Clin Neuropsychol*. 2025;39(2):424-438.

39. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. *Stat Comput*. 2017;27(5):1413-1432.

40. Kwak S, Shin M, Kim H, et al. Moderating effect of cognitive reserve on the association between grey matter atrophy and memory varies with age in older adults. *Psychogeriatrics*. 2020;20(1):87-95.

41. James C, Morand S, Barcellona-Lehmann S, Michel CM, Schnider A. Neural transition from short- to long-term memory and the medial temporal lobe: a human evoked-potential study. *Hippocampus*. 2009;19(4):371-378.

42. Boona ME, Melisa RJF, Olde Rikkerta MG, Kesselsa RPC. Atrophy in the medial temporal lobe is specifically associated with encoding and storage of verbal information in MCI and Alzheimer patients. *Journal of Neurology Research*. 2011;1(1):11-15.

43. Yan S, Zheng C, Paranjpe MD, et al. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. *Brain*. 2021;144(10):3201-3211.

44. Lowe VJ, Wiste HJ, Senjem ML, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. *Brain*. 2018;141(1):271-287.

45. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain*. 2016;139(Pt 5):1551-1567.

46. Buckley RF, Mormino EC, Rabin JS, et al. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. *JAMA Neurol*. 2019;76(5):542-551.

47. Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer's disease and common neuropathologies of aging. *Acta Neuropathol*. 2018;136(6):887-900.

48. Chow TE, Veziris CR, Mundada N, et al. Medial temporal lobe tau aggregation relates to divergent cognitive and emotional empathy abilities in Alzheimer's disease. *J Alzheimers Dis*. 2023;96(1):313-328.

49. Terao CM, Alexander MW, Chalmers RP, et al. Identifying cognitive test scores associated with early tau burden in Alzheimer's disease. *Alzheimers Dement (Amst)*. 2025;17(1):e70052.

50. Banks SJ, Andrews MJ, Digma L, et al. Sex differences in Alzheimer's disease: do differences in tau explain the verbal memory gap? *Neurobiol Aging*. 2021;107:70-77.

51. Simons M, Levin J, Dichgans M. Tipping points in neurodegeneration. *Neuron*. 2023;111(19):2954-2968.

52. Merlini S, Bedrick EJ, Brinton RD, Vitali F. Multisystem failure, tipping points, and risk of Alzheimer's disease. *Alzheimers Dement*. 2025;21(5):e70249.

53. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21.

54. Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL, Alzheimer's Disease Neuroimaging Initiative. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. *Alzheimers Dement*. 2025;21(1):e14467.

55. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562.

56. Leuzy A, Raket LL, Villemagne VL, et al. Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model. *Alzheimers Dement*. 2024;20(9):5833-5848.